Effect of levosimendan on B-type natriuretic peptide levels in patients with advanced heart failure: a meta-analysis.
- Author:
Zhong-dong XU
1
;
Wei-xiong HE
;
Yi-fan ZHAO
;
Shu-xuan XIA
;
Bo HE
;
Tao YANG
;
De-xiong CAO
;
Shu-ling PENG
;
Jue LI
;
Ming-hui CAO
Author Information
- Publication Type:Journal Article
- MeSH: Cardiotonic Agents; therapeutic use; Heart Failure; blood; drug therapy; Humans; Hydrazones; therapeutic use; Natriuretic Peptide, Brain; blood; Pyridazines; therapeutic use
- From: Journal of Southern Medical University 2009;29(10):2027-2029
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo conduct a meta-analysis of the effect of levosimendan on B-type natriuretic peptide (BNP) levels and evaluate the therapeutic effect of levosimendan on advanced heart failure.
METHODSA meta-analysis was performed on the selected data to analyze the effect of levosimendan on BNP levels.
RESULTSLevosimendan decreased BNP by a mean of 337.66 [95%CI (-296.30, -379.02)] pg/ml 24 h after the administration, and by 259.92 [95%CI (-195.76, -324.08)] pg/ml at 48 h, and by 123.09 [95%CI(-53.32,-195.86)] pg/ml at 1 week. Levosimendan resulted in improvements of the cardiac function by about 29%, 22%, and 10% at 24 h, 48 h and 1 week after the administration.
CONCLUSIONLevosimendan produces favorable effects on the cardiac functions and BNP levels.
